Show simple item record

dc.contributor.authorOzdemir, Tulay
dc.contributor.authorNar, Rukiye
dc.contributor.authorKilinc, Veli
dc.contributor.authorAlacam, Hasan
dc.contributor.authorSalis, Osman
dc.contributor.authorDuzgun, Aynur
dc.contributor.authorBedir, Abdulkerim
dc.date.accessioned2020-06-21T14:17:38Z
dc.date.available2020-06-21T14:17:38Z
dc.date.issued2012
dc.identifier.issn1084-9785
dc.identifier.urihttps://doi.org/10.1089/cbr.2011.1138
dc.identifier.urihttps://hdl.handle.net/20.500.12712/16309
dc.descriptionWOS: 000309974500001en_US
dc.descriptionPubMed: 22757644en_US
dc.description.abstractOuabain is a cardiotonic steroid and specific inhibitor of the Na+/K+-ATPase. The relationship between ouabain treatment and the unfolded protein response (UPR) in cells is not precisely understood. Therefore, we studied the possible effects of ouabain on proliferation, apoptosis, and the UPR. HepG2 cells were cultured overnight and then treated with various concentrations of ouabain (0.75 to 750 nM) in the absence or presence of 10 mM 2-deoxyglucose (2-DG) for 48 hours. We also used real-time polymerase chain reaction to obtain quantitative measurements of expression levels of Grp78, Grp94, CHOP, MTJ-1, HKII, MDR-1, MRP-1, HO-1, and Par-4. Cell number, viability, and proliferation of HepG2 cells were monitored with a real-time cell analyzer system (xCELLigence). We show that ouabain modulates the UPR transcription program and induces cell death in glucose-deprived tumor cells. Ouabain at all concentrations showed no cytotoxicity whereas all concentrations were very effective under 2-DG stress conditions. Our findings show that disruption of the UPR during glucose deprivation could be an attractive approach for selective cancer cell killing and could provide a chemical basis for developing UPR-targeting drugs against solid tumors. Ouabain use as an adjunct to conventional cancer therapy also warrants vigorous investigation.en_US
dc.description.sponsorshipOndokuz Mayis UniversityOndokuz Mayis University [PYO.TIP. 1901 09 001]en_US
dc.description.sponsorshipThis study was supported by grants from the Ondokuz Mayis University Research Fund, project number PYO.TIP. 1901 09 001.en_US
dc.language.isoengen_US
dc.publisherMary Ann Liebert Incen_US
dc.relation.isversionof10.1089/cbr.2011.1138en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject2-deoxyglucoseen_US
dc.subjectCHOPen_US
dc.subjectGrp78en_US
dc.subjectHepG2en_US
dc.subjectouabainen_US
dc.subjectunfolded protein responseen_US
dc.titleOuabain Targets the Unfolded Protein Response for Selective Killing of HepG2 Cells During Glucose Deprivationen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume27en_US
dc.identifier.issue8en_US
dc.identifier.startpage457en_US
dc.identifier.endpage463en_US
dc.relation.journalCancer Biotherapy and Radiopharmaceuticalsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record